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Abstract: “Nonallergic vasomotor rhinitis” (also referred to as
nonallergic rhinitis and/or idiopathic rhinitis) is a term that has been
used to describe a common nasal condition of unclear pathophysi-
ology. The lack of straightforward diagnostic criteria is limiting;
research for better treatment options requires the definition of
homogeneous populations characterized by well-defined inclusion
and exclusion criteria. Following considerable discussion and coun-
terpoints at a roundtable conference convened in December 2008,
we proposed to change the terminology to reference this condition as
“nonallergic rhinopathy.” Nonallergic rhinopathy is a chronic nasal
condition with symptoms that may be perennial, persistent, inter-
mittent, or seasonal and/or elicited by recognized triggers. There is
a well-recognized set of clinical exposures that lead to the symp-
toms, predominantly congestion and rhinorrhea. The clinical char-
acteristics as outlined provide well-defined inclusion and exclusion
criteria that should permit precise identification of patients for
participation in clinical trials.
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The papers presented in the first part of these proceedingswere delivered at the roundtable meeting (December 13,
2008, Washington, DC) with the intent of reaching a consen-
sus definition of nonallergic rhinopathy (formerly referred to
as vasomotor rhinitis, nonallergic rhinitis, and/or idiopathic
rhinitis). Consensus was attained following considerable dis-
cussion and counterpoints by all participants.
I. “Nonallergic rhinopathy” (NAR) is recommended to re-
place the term vasomotor rhinitis (VMR). VMR suggests
that intrinsic nasal vascular and glandular abnormalities
are the principle physiological causes of inflammation of
the nasal mucous membrane. However, current informa-
tion suggests that NAR is probably due to neurosensory
abnormalities and does not include inflammation as an
important component. Thus, we believe that it is more
accurate to term this condition a rhinopathy (a disorder of
the nose) rather than a form of rhinitis (inflammation of
the nose). The single unequivocal criterion for these
patients is that they are not allergic: nonallergic rhinopa-
thy is a more appropriate term for this disorder.
II. NAR is defined by clinical characteristics, which are
summarized below and described in detail in the series of
related articles from the consensus conference.
A. NAR is a chronic disease with some, but not neces-




2. Other associated symptoms:
a. Postnasal drip in the absence of a pharyngeal
cause of mucus hypersecretion or acid reflux
disease.
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b. Throat clearing.
c. Cough.





B. Symptoms of NAR may be perennial, persistent, or
seasonal (i.e., climatic–see below) and/or elicited
by defined triggers. These triggers may include the
following:
1. Cold air.
2. Changes in climate (such as temperature, humidity,
and barometric pressure).
3. Strong smells (such as perfume, cooking smells,
flowers, and chemical odors).
4. Environmental tobacco smoke.
5. Changes in sexual hormone levels.
6. Pollutants and chemicals (e.g., volatile organics).
7. Exercise.
8. Alcohol ingestion.
Symptoms may be described as perennial, persistent,
intermittent, or seasonal and occur in response to
climatic shifts in temperature, humidity, and baromet-
ric pressure. A patient’s symptoms may be brought on
by 1 or more of the defined precipitants. There are no
current data indicating that patients responsive to
environmental climate changes as a trigger differ from
those triggered by perfumes or strong smells. More-
over, there is no current information suggesting that a
patient with this set of clinical symptoms and charac-
teristics, and for whom no triggers are identified,
differ from patients with clearly defined triggers.
Thus, NAR may be diagnosed regardless of the pres-
ence or the absence of defined triggers.
C. There is a female-to-male incidence ratio for NAR of
2:1 to 3:1.
D. NAR presents predominantly with adult onset.
E. The nasal mucosa in NAR usually appears normal, but
may sometimes appear red and beefy with scant mucus.
F. NAR is associated with negative or irrelevant skin
prick tests or antigen-specific IgE tests (formerly re-
ferred to as radioallergosorbent tests).
G. NAR may present with concomitant conditions such
as the following:
1. Food-related rhinorrhea.
2. Mild nasal eosinophilia (5%).
3. Eustachian tube dysfunction (ear pressure/popping/
pain).
4. Senile rhinitis.
H. NAR symptoms are not caused by other known etio-
logical factors for rhinopathy, such as the following:
1. Chronic rhinosinusitis or nasal polyps.
2. Nonallergic rhinitis with eosinophilia syndrome
with nasal eosinophilia 5%.
3. Aspirin-related chronic rhinosinusitis, nasal polyps,
or asthma, although NAR is usually seen as one of the
clinical characteristics of aspirin-exacerbated respira-
tory disease.
4. Infectious rhinitis or rhinosinusitis (eg, viral upper
respiratory infections, bacterial/fungal rhinosinus-
itis, and bacterial rhinitis).
5. Anatomical abnormalities.
6. Drug usage (e.g., adverse effect of systemic med-
ication and excess use of topical decongestants).
7. Cerebrospinal fluid leak.
8. Pregnancy.
III. In summary, nonallergic rhinopathy is a chronic condition
with symptoms that may be perennial and/or elicited by
recognized triggers. The clinical characteristics provide
well-defined inclusion and exclusion criteria that should
permit precise identification of patients with this disease
category for further study. The next issue of this journal
will include our recommendations for those inclusion and
exclusion criteria based on the in-depth discussion and
counterpoints at the roundtable meeting.
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